1 min read
Moleculin Biotech Cuts Third-Quarter Net Loss 74% to $6.5 Million
Research and development expenses increased 20% to $4.5 million. The company had $7.3 million in cash and cash equivalents at Sept. 30, 2026.

Moleculin Biotech, Inc. posted a $6.5 million third-quarter net loss, down 74% year over year, primarily because a large warrant-related noncash charge from the year-earlier period did not recur.
The prior-year period included a $20.6 million noncash loss tied to the issuance of warrant liabilities. Research and development expenses rose 20% to $4.5 million.
Diluted loss per share was $9.59, compared with $340.43 for the same quarter a year earlier. Moleculin had $7.3 million in cash and cash equivalents at Sept. 30, 2026, down from $8.9 million at Dec. 31, 2025.